SMARCA2 and cancer: Use of the bromodomain-binding small molecule inhibitor alone failed to inhibit proliferation, indicating that complete ablation of the protein is required for the anti-proliferative effect, suggesting that the total protein degradation approach is hugely promising as a therapeutic avenue for SMARCA2/4-dependent cancers.